Evidence map›Paper›PMID 25370568›Full record

ArticleMolecular medicine reports2015

The role of death receptor 3 in the biological behavior of hepatocellular carcinoma cells.

You Cheng Zhang, Liu Qing Guo, Xiao Chen, Gen Nian Wang, Ri Ni, Man Cai Wang, Feng Xian Wei

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. [The effects of macrophages with high expression of TL1A on activation and proliferation of hepatic stellate cells in vitro].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

You Cheng ZhangDepartment of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China.
Liu Qing GuoDepartment of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China.
Xiao ChenDepartment of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China.
Gen Nian WangHepato‑Biliary‑Pancreatic Institute, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China.
Ri NiHepato‑Biliary‑Pancreatic Institute, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China.
Man Cai WangHepato‑Biliary‑Pancreatic Institute, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China.
Feng Xian WeiHepato‑Biliary‑Pancreatic Institute, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China.
Lanzhou University · CNLanzhou University Second Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Death receptor 3 (DR3) belongs to the tumor necrosis factor (TNF) receptor superfamily, primarily found in lymphoid tissues. Reports have determined that DR3 may also be distributed in numerous types of tumors. Therefore, it is thought that DR3 may have an important role in the process of tumorigenesis. The aim of the present study was to observe the effect of silencing DR3 expression on hepatocarcinoma cell growth, apoptosis and invasion in order to elucidate the role of DR3 in tumor development. The hepatocarcinoma cell lines (HepG2, Huh7, SMMC7721 and Bel‑7402) and normal human liver cells (HL‑7702) were transfected with three stealth RNA interference (RNAi) sequences that target the DR3 gene. Reverse transcription quantitative polymerase chain reaction was used to detect the expression levels of DR3 in hepatocarcinoma cell lines and normal liver HL‑7702 cells. MTT assay and flow cytometry (FCM) were used to determine the rates of cell proliferation and apoptosis, respectively. Following silencing of the DR3 gene, western blot analysis was used to determine the protein expression of P53, Fas, Caspase8, nuclear factor kappa‑light‑chain‑enhancer of activated B cells (NF‑κB) and Caspase3. DR3 messenger RNA (mRNA) expression in hepatocarcinoma cell lines was significantly increased compared with that in the normal liver cell line. Three targeted DR3 gene small interfering RNAs significantly inhibited DR3 gene expression in Bel‑7402 cells at the nucleic acid level. AF02670.1_stealth_883 and cocktail demonstrated the most efficient inhibition of DR3 gene expression at 48 and 72 h following transfection, with mRNA inhibition rates of 89.46 and 92.75%, and 90.53 and 94.25% (P<0.01), respectively. Cell viability was significantly reduced by AF02670.1_stealth_883 and RNAi cocktail at 24, 48 and 72 h following transfection. The inhibition rates of cell proliferation were 50.76 and 61.76% (P<0.05) at 72 h following transfection. FCM revealed that AF02670.1_stealth_883 and RNAi cocktail also induced apoptosis in Bel‑7402 cells at 72 h following transfection. Reduction of NF‑κB and P53 levels was observed (P<0.05) in Bel‑7402 cells following DR3 silencing, whereas levels of Fas, Caspase3 and Caspase8 were markedly elevated (P<0.05). DR3 expression levels in hepatocellular carcinoma cells were significantly higher than those in normal cells. DR3 silencing effectively inhibited proliferation and invasion of hepatocellular carcinoma cells in vitro. However, silencing of the DR3 gene affect levels of apoptosis antigen‑3 ligand in cells, therefore indicating that it may be involved with other pathways that regulate apoptosis in HCCs. In conclusion, the results of the present study indicated that DR3 may be a promising therapeutic target molecule for further study of hepatocellular carcinoma gene therapy.

Indexed as

ApoptosisCarcinoma, HepatocellularCaspase 3Caspase 8Cell LineCell MovementCell Proliferationfas ReceptorHepatocytesHep G2 CellsHumansLiver NeoplasmsNF-kappa BReceptors, Tumor Necrosis Factor, Member 25RNA InterferenceRNA, MessengerCaspase 3Caspase 8FAS protein, humanfas ReceptorNF-kappa BReceptors, Tumor Necrosis Factor, Member 25RNA, MessengerRNA, Small InterferingTumor Suppressor Protein p53

Identifiers

PMID25370568
PMCPMC4262488
OpenAlexW2018427162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.